{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:53:14Z","timestamp":1792212794774,"version":"4.4.0"},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,11,6]],"date-time":"2016-11-06T00:00:00Z","timestamp":1478390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Pharmacovigilance databases are usually used to detect new potential signals that are relevant for drug safety. They are seldom used for explanatory purposes, e.g. to understand the mechanisms of adverse drug reactions (ADRs). The aim of the present study was to combine pharmacovigilance and pharmacodynamic data to investigate the association between dopamine D2, serotonin 5HT2A, and muscarinic M1 receptor occupancy and the risks of antipsychotic drug (AP)\u2010induced movement disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>First, we performed a case\u2013noncase analysis using spontaneous reports from the World Health Organization (WHO) Global Individual Case Safety Report (ICSR) database, VigiBase\u00ae. We thus measured the risk of reporting movement disorders compared with all other ADRs [expressed as a reporting odds ratio (ROR)] for APs. Second, we performed a linear regression analysis to explore the association between the estimated risk of reporting for individual drugs and their receptor occupancy properties, for D2, 5HT2A and M1 receptors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with second\u2010generation APs, first\u2010generation APs were found to be significantly more associated with the reporting of movement disorders in general but also with dystonia, Parkinsonism, akathisia and tardive dyskinesia, irrespective of gender. A significant inverse correlation was found between the ROR for movement disorders and the receptor occupancy of 5HT2A [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001; R\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00.51; slope\u00a0=\u00a0\u22120.014; 95% confidence interval (CI) (\u22120.029, 0.001)], M1 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001; R\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00.56; slope\u00a0=\u00a0\u22120.014; 95% CI (\u22120.028, 0.001) but not D2 dopamine (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.54; R\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00.02; slope\u00a0=\u00a0\u22120.003; 95% CI (\u22120.007, 0.001) receptors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using the example of AP\u2010induced movement disorders, the present study underlines the value of the pharmacoepidemiological\u2013pharmacodynamic method to explore ADR mechanisms in humans and real\u2010life settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.13145","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T03:33:18Z","timestamp":1475206398000},"page":"612-622","source":"Crossref","is-referenced-by-count":40,"title":["An original pharmacoepidemiological\u2013pharmacodynamic method: application to antipsychotic\u2010induced movement disorders"],"prefix":"10.1111","volume":"83","author":[{"given":"Thi Thu Ha","family":"Nguyen","sequence":"first","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Facult\u00e9 de M\u00e9decine de Toulouse Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"INSERM UMR 1027, Unit\u00e9 de Pharmaco\u00e9pid\u00e9miologie Universit\u00e9 de Toulouse  Toulouse France"},{"name":"Facult\u00e9 de M\u00e9decine et de Pharmacie Universit\u00e9 Nationale du Vietnam \u2013 Hanoi  Hanoi Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pharmacologie M\u00e9dicale, INSERM, U1219\u2010Pharmacoepidemiology Universit\u00e9 de Bordeaux  F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Louis","family":"Montastruc","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Facult\u00e9 de M\u00e9decine de Toulouse Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"INSERM UMR 1027, Unit\u00e9 de Pharmaco\u00e9pid\u00e9miologie Universit\u00e9 de Toulouse  Toulouse France"},{"name":"D\u00e9partement de Pharmacologie M\u00e9dicale, INSERM, U1219\u2010Pharmacoepidemiology Universit\u00e9 de Bordeaux  F\u201033000 Bordeaux France"},{"name":"CIC INSERM 1436 Universit\u00e9 de Toulouse  Toulouse France"},{"name":"NeuroToul Centre of Excellence in Neurodegeneration Universit\u00e9 et Centre Hospitalier Universitaire  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Facult\u00e9 de M\u00e9decine de Toulouse Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"INSERM UMR 1027, Unit\u00e9 de Pharmaco\u00e9pid\u00e9miologie Universit\u00e9 de Toulouse  Toulouse France"},{"name":"CIC INSERM 1436 Universit\u00e9 de Toulouse  Toulouse France"},{"name":"NeuroToul Centre of Excellence in Neurodegeneration Universit\u00e9 et Centre Hospitalier Universitaire  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rousseau","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Facult\u00e9 de M\u00e9decine de Toulouse Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"INSERM UMR 1027, Unit\u00e9 de Pharmaco\u00e9pid\u00e9miologie Universit\u00e9 de Toulouse  Toulouse France"},{"name":"Centre Midi\u2010Pyr\u00e9n\u00e9es de PharmacoVigilance, de Pharmaco\u00e9pid\u00e9miologie et d'Informations sur le M\u00e9dicament Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"CIC INSERM 1436 Universit\u00e9 de Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Facult\u00e9 de M\u00e9decine de Toulouse Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"CIC INSERM 1436 Universit\u00e9 de Toulouse  Toulouse France"},{"name":"NeuroToul Centre of Excellence in Neurodegeneration Universit\u00e9 et Centre Hospitalier Universitaire  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"B\u00e9gaud","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pharmacologie M\u00e9dicale, INSERM, U1219\u2010Pharmacoepidemiology Universit\u00e9 de Bordeaux  F\u201033000 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Facult\u00e9 de M\u00e9decine de Toulouse Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"D\u00e9partement de Pharmacologie M\u00e9dicale, INSERM, U1219\u2010Pharmacoepidemiology Universit\u00e9 de Bordeaux  F\u201033000 Bordeaux France"},{"name":"Centre Midi\u2010Pyr\u00e9n\u00e9es de PharmacoVigilance, de Pharmaco\u00e9pid\u00e9miologie et d'Informations sur le M\u00e9dicament Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"CIC INSERM 1436 Universit\u00e9 de Toulouse  Toulouse France"},{"name":"NeuroToul Centre of Excellence in Neurodegeneration Universit\u00e9 et Centre Hospitalier Universitaire  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1037"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13348"},{"key":"e_1_2_10_4_1","unstructured":"WHO.Pharmacovigilance [online]. Available athttp:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/pharmvigi\/en\/(last accessed 26 February 2016)."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1058"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000094"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200700026"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124100-00001"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1199"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002808702101114"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182214aad"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.141424"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.07.010"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2010051"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0339-z"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.10.010"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0801"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.02.012"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200501"},{"key":"e_1_2_10_22_1","first-page":"1180","article-title":"The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center","volume":"28","author":"Lindquist M","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"e_1_2_10_24_1","unstructured":"Uppsala Monitoring Centre. VigiLyze [online]. Available athttp:\/\/who\u2010umc.org\/DynPage.aspx?7252&mn3=7254&mn4=7695(last accessed 9 March 2016)."},{"key":"e_1_2_10_25_1","unstructured":"MedDRA. [online]. Available athttp:\/\/www.meddra.org\/(last accessed 9 March 2016)."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-009-0912-5"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10111"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"e_1_2_10_29_1","volume-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","author":"Brunton L","year":"2011"},{"key":"e_1_2_10_30_1","volume-title":"The Complete Drug Reference (38th revised edn)","author":"Martindale BA","year":"2014"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq061"},{"key":"e_1_2_10_32_1","unstructured":"IUPHAR \u2013 International Union of Basic and Clinical Pharmacology website [online]. Available athttp:\/\/www.iuphar.org\/(last accessed 9 May 2013)."},{"key":"e_1_2_10_33_1","unstructured":"PDSP.Home page [online]. Available athttps:\/\/pdspdb.unc.edu\/pdspWeb\/(last accessed 9 March 2016)."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13347"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2010.10.002"},{"key":"e_1_2_10_38_1","first-page":"649","article-title":"The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians","volume":"23","author":"Naber D","year":"2009","journal-title":"CNS Drugs"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/10673220600748486"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e318198776d"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1994.tb05830.x"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760130040006"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi092"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00881.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13145","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T09:53:58Z","timestamp":1696240438000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/bcp.13145"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13145","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,6]]}}}